Humana stock performance snapshot

Humana (HUM) has seen mixed share performance recently, with the stock down over the past month and past 3 months, and also negative on a 1 year and longer term total return basis.

At a last close of US$190.54, the health insurer and senior care provider reports annual revenue of about US$129.7b and net income of US$1.19b.

Humana's share price has seen a modest 1 day gain and a slight 7 day rise, but these moves sit against a weaker picture. The year to date share price return and multi year total shareholder returns are both in decline, suggesting momentum has been fading rather than building.

If this trend has you reassessing your watchlist, it could be a good moment to widen the lens and look at 27 healthcare AI stocks that might fit a different part of your portfolio.

With Humana trading at US$190.54 and sitting at a sizeable intrinsic discount, yet still carrying a lower value score of 5, you have to ask: is this weakness a genuine opening, or is the market already factoring in future growth?

Most Popular Narrative: 10.5% Undervalued

Humana's most followed valuation narrative, according to yiannisz, points to a fair value of $212.87 against the recent share price of $190.54, framing the current discount as more than just short term share price weakness.

Humana (NYSE: HUM) is navigating a regulatory environment that is becoming increasingly unforgiving. While Medicare Advantage has been a powerful growth engine for insurers over the past decade, recent developments suggest that oversight is intensifying, and the margin for error is shrinking. Across the industry, regulators are sharpening their focus on how health plans document risk adjustment data and apply prior authorization standards. What once felt like routine administrative processes are now front-and-center enforcement targets. As Medicare Advantage enrollment grows and billing operations become more data-driven, oversight agencies are paying closer attention to documentation accuracy and determinations of medical necessity. For Humana, this shift carries real implications.

The fair value here is not a back of the envelope guess. It leans on revenue growth assumptions, slim but persistent margins, and a profit multiple that reflects Medicare Advantage staying central to the story. Want to see how those moving parts line up in detail, and which inputs matter most if the narrative shifts?

Result: Fair Value of $212.87 (UNDERVALUED)

However, Medicare Advantage audit findings or tighter documentation rules, as well as any pressure on already slim margins, could quickly challenge the 10.5% undervalued narrative.

Next Steps

If this mix of pressure points and potential upside leaves you undecided, now is the time to look closely at the underlying data and form your own view. Start with 3 key rewards and 2 important warning signs.

Looking for more investment ideas?

If Humana has you thinking more carefully about where your money works hardest, do not stop here. Use the screener to line up your next candidates.

• Target dependable income by scanning for 15 dividend fortresses that could help anchor the income side of your portfolio.
• Hunt for value by checking out 47 high quality undervalued stocks, where the focus is on companies that combine quality fundamentals with attractive pricing.
• Prioritise resilience by reviewing 76 resilient stocks with low risk scores, highlighting businesses with lower risk profiles that may suit a steadier approach.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.